Association between adiponectin, insulin resistance, and endometrial cancer

Pamela T. Soliman, Diana Wu, Guillermo Tortolero-Luna, Kathleen M. Schmeler, Brian Slomovitz, Molly S. Bray, David M. Gershenson, Karen H. Lu

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

BACKGROUND. Obesity is a well known risk factor for the development of endometrial cancer; however, weight alone does not account for all cases. The authors hypothesized that insulin resistance also contributes to an increased risk for endometrial cancer. Adiponectin is a protein secreted by adipose cells and has been shown to be a surrogate marker for insulin resistance, with low levels of adiponectin correlated with hyperinsulinemia and degree of insulin resistance. The purpose of the current study was to determine whether there was an independent association between adiponectin level and endometrial cancer. METHODS. A case-control study was performed on 117 endometrial cancer patients (cases) and 238 women with' no history of cancer (controls). Serum adiponectin levels were measured using enzyme-linked immunoadsorbent assay and examined for their association with endometrial cancer. Univariate and multivariate logistic regression analyses were performed with adjustment for confounding factors. RESULTS. The mean serum adiponectin levels were significantly lower among cases (88.8 ± 63.3 ng/mL) than among controls (148.2 ± 68.3; P<.001). This inverse correlation continued to be observed after controlling for age, body mass index, diabetes, and hypertension. Cases were significantly more likely to have serum adiponectin levels in the lowest (odds ratio [OR] of 10.5; 95% confidence interval [95% CI], 4.49-24.57 [P<.001]) and intermediate tertiles (OR of 2.5; 95% CI, 1.01-6.21 [P = .05]) when compared with controls. CONCLUSIONS. Adiponectin level was found to be independently and inversely associated with endometrial cancer. Women with endometrial cancer were more likely to have low adiponectin levels than controls, even after adjusting for body mass index. This suggested that insulin resistance is independently associated with endometrial cancer.

Original languageEnglish (US)
Pages (from-to)2376-2381
Number of pages6
JournalCancer
Volume106
Issue number11
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

Fingerprint

Adiponectin
Endometrial Neoplasms
Insulin Resistance
Body Mass Index
Serum
Odds Ratio
Confidence Intervals
Immunosorbents
Hyperinsulinism
Case-Control Studies
Obesity
Biomarkers
Logistic Models
Regression Analysis
Hypertension
Weights and Measures
Enzymes

Keywords

  • Adiponectin
  • Endometrial cancer
  • Gynecologic malignancy
  • Insulin resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Soliman, P. T., Wu, D., Tortolero-Luna, G., Schmeler, K. M., Slomovitz, B., Bray, M. S., ... Lu, K. H. (2006). Association between adiponectin, insulin resistance, and endometrial cancer. Cancer, 106(11), 2376-2381. https://doi.org/10.1002/cncr.21866

Association between adiponectin, insulin resistance, and endometrial cancer. / Soliman, Pamela T.; Wu, Diana; Tortolero-Luna, Guillermo; Schmeler, Kathleen M.; Slomovitz, Brian; Bray, Molly S.; Gershenson, David M.; Lu, Karen H.

In: Cancer, Vol. 106, No. 11, 01.06.2006, p. 2376-2381.

Research output: Contribution to journalArticle

Soliman, PT, Wu, D, Tortolero-Luna, G, Schmeler, KM, Slomovitz, B, Bray, MS, Gershenson, DM & Lu, KH 2006, 'Association between adiponectin, insulin resistance, and endometrial cancer', Cancer, vol. 106, no. 11, pp. 2376-2381. https://doi.org/10.1002/cncr.21866
Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz B, Bray MS et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006 Jun 1;106(11):2376-2381. https://doi.org/10.1002/cncr.21866
Soliman, Pamela T. ; Wu, Diana ; Tortolero-Luna, Guillermo ; Schmeler, Kathleen M. ; Slomovitz, Brian ; Bray, Molly S. ; Gershenson, David M. ; Lu, Karen H. / Association between adiponectin, insulin resistance, and endometrial cancer. In: Cancer. 2006 ; Vol. 106, No. 11. pp. 2376-2381.
@article{5f07b4b5a6f94f12b2c1167be7381746,
title = "Association between adiponectin, insulin resistance, and endometrial cancer",
abstract = "BACKGROUND. Obesity is a well known risk factor for the development of endometrial cancer; however, weight alone does not account for all cases. The authors hypothesized that insulin resistance also contributes to an increased risk for endometrial cancer. Adiponectin is a protein secreted by adipose cells and has been shown to be a surrogate marker for insulin resistance, with low levels of adiponectin correlated with hyperinsulinemia and degree of insulin resistance. The purpose of the current study was to determine whether there was an independent association between adiponectin level and endometrial cancer. METHODS. A case-control study was performed on 117 endometrial cancer patients (cases) and 238 women with' no history of cancer (controls). Serum adiponectin levels were measured using enzyme-linked immunoadsorbent assay and examined for their association with endometrial cancer. Univariate and multivariate logistic regression analyses were performed with adjustment for confounding factors. RESULTS. The mean serum adiponectin levels were significantly lower among cases (88.8 ± 63.3 ng/mL) than among controls (148.2 ± 68.3; P<.001). This inverse correlation continued to be observed after controlling for age, body mass index, diabetes, and hypertension. Cases were significantly more likely to have serum adiponectin levels in the lowest (odds ratio [OR] of 10.5; 95{\%} confidence interval [95{\%} CI], 4.49-24.57 [P<.001]) and intermediate tertiles (OR of 2.5; 95{\%} CI, 1.01-6.21 [P = .05]) when compared with controls. CONCLUSIONS. Adiponectin level was found to be independently and inversely associated with endometrial cancer. Women with endometrial cancer were more likely to have low adiponectin levels than controls, even after adjusting for body mass index. This suggested that insulin resistance is independently associated with endometrial cancer.",
keywords = "Adiponectin, Endometrial cancer, Gynecologic malignancy, Insulin resistance",
author = "Soliman, {Pamela T.} and Diana Wu and Guillermo Tortolero-Luna and Schmeler, {Kathleen M.} and Brian Slomovitz and Bray, {Molly S.} and Gershenson, {David M.} and Lu, {Karen H.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1002/cncr.21866",
language = "English (US)",
volume = "106",
pages = "2376--2381",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Association between adiponectin, insulin resistance, and endometrial cancer

AU - Soliman, Pamela T.

AU - Wu, Diana

AU - Tortolero-Luna, Guillermo

AU - Schmeler, Kathleen M.

AU - Slomovitz, Brian

AU - Bray, Molly S.

AU - Gershenson, David M.

AU - Lu, Karen H.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - BACKGROUND. Obesity is a well known risk factor for the development of endometrial cancer; however, weight alone does not account for all cases. The authors hypothesized that insulin resistance also contributes to an increased risk for endometrial cancer. Adiponectin is a protein secreted by adipose cells and has been shown to be a surrogate marker for insulin resistance, with low levels of adiponectin correlated with hyperinsulinemia and degree of insulin resistance. The purpose of the current study was to determine whether there was an independent association between adiponectin level and endometrial cancer. METHODS. A case-control study was performed on 117 endometrial cancer patients (cases) and 238 women with' no history of cancer (controls). Serum adiponectin levels were measured using enzyme-linked immunoadsorbent assay and examined for their association with endometrial cancer. Univariate and multivariate logistic regression analyses were performed with adjustment for confounding factors. RESULTS. The mean serum adiponectin levels were significantly lower among cases (88.8 ± 63.3 ng/mL) than among controls (148.2 ± 68.3; P<.001). This inverse correlation continued to be observed after controlling for age, body mass index, diabetes, and hypertension. Cases were significantly more likely to have serum adiponectin levels in the lowest (odds ratio [OR] of 10.5; 95% confidence interval [95% CI], 4.49-24.57 [P<.001]) and intermediate tertiles (OR of 2.5; 95% CI, 1.01-6.21 [P = .05]) when compared with controls. CONCLUSIONS. Adiponectin level was found to be independently and inversely associated with endometrial cancer. Women with endometrial cancer were more likely to have low adiponectin levels than controls, even after adjusting for body mass index. This suggested that insulin resistance is independently associated with endometrial cancer.

AB - BACKGROUND. Obesity is a well known risk factor for the development of endometrial cancer; however, weight alone does not account for all cases. The authors hypothesized that insulin resistance also contributes to an increased risk for endometrial cancer. Adiponectin is a protein secreted by adipose cells and has been shown to be a surrogate marker for insulin resistance, with low levels of adiponectin correlated with hyperinsulinemia and degree of insulin resistance. The purpose of the current study was to determine whether there was an independent association between adiponectin level and endometrial cancer. METHODS. A case-control study was performed on 117 endometrial cancer patients (cases) and 238 women with' no history of cancer (controls). Serum adiponectin levels were measured using enzyme-linked immunoadsorbent assay and examined for their association with endometrial cancer. Univariate and multivariate logistic regression analyses were performed with adjustment for confounding factors. RESULTS. The mean serum adiponectin levels were significantly lower among cases (88.8 ± 63.3 ng/mL) than among controls (148.2 ± 68.3; P<.001). This inverse correlation continued to be observed after controlling for age, body mass index, diabetes, and hypertension. Cases were significantly more likely to have serum adiponectin levels in the lowest (odds ratio [OR] of 10.5; 95% confidence interval [95% CI], 4.49-24.57 [P<.001]) and intermediate tertiles (OR of 2.5; 95% CI, 1.01-6.21 [P = .05]) when compared with controls. CONCLUSIONS. Adiponectin level was found to be independently and inversely associated with endometrial cancer. Women with endometrial cancer were more likely to have low adiponectin levels than controls, even after adjusting for body mass index. This suggested that insulin resistance is independently associated with endometrial cancer.

KW - Adiponectin

KW - Endometrial cancer

KW - Gynecologic malignancy

KW - Insulin resistance

UR - http://www.scopus.com/inward/record.url?scp=33646874133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646874133&partnerID=8YFLogxK

U2 - 10.1002/cncr.21866

DO - 10.1002/cncr.21866

M3 - Article

C2 - 16639730

AN - SCOPUS:33646874133

VL - 106

SP - 2376

EP - 2381

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -